Pharma News

MB-272 by Gilead Sciences for Autoimmune Disorders: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MB-272 overview

MB-272 is under development for the treatment of autoimmune diseases. It acts by targeting B and T lymphocyte attenuator (BTLA).

Gilead Sciences overview

Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It is engaged in the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer, and human immunodeficiency virus (HIV) infection. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. It has manufacturing facilities in Edmonton, Alberta, Canada; Foster City, San Dimas, Oceanside, California; and Cork, Ireland among others. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.

For a complete picture of MB-272’s drug-specific PTSR and LoA scores, buy the report here.




Source link
#MB272 #Gilead #Sciences #Autoimmune #Disorders #Likelihood #Approval

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *